7,561.75

-12.75

-0.17%

51,914.00

-219.00

-0.42%

28,117.25

-10.25

-0.04%

Russell 2000 Futures

2,813.80

-4.00

-0.14%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,934.70

-34.90

-0.88%

76,532.91

-1,504.80

-1.93%

Crude Oil Dec 26

97.46

+1.00

+1.04%

US Private Equity

10,836.30

-14.33

-0.13%

TSXV - Delayed Quote CAD

Telo Genomics Corp. (TELO.V)

0.0500 0.0000 (0.00%)

At close: October 30 at 2:03:49 PM EDT

Loading Chart for TELO.V

Chart Range Bar

Interval:

In partnership with ChartIQ

TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing

TELO Genomics Expands Multi-Center Clinical Studies to Advance Comparative Validation of TELO-MRD Against Next-Generation Sequencing

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Telo Genomics Announces Clinical Research Results Evidencing Utility of Its Telomere Analysis Platform in Predicting Multiple Myeloma Relapse

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma

Telo Genomics Announces Termination of Investor Relations Agreement

Telo Genomics Announces Termination of Investor Relations Agreement

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman

Telo Genomics Grants Stock Options

Telo Genomics Grants Stock Options

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Telo Genomics Closes Second and Final Tranche of Convertible Debentures Financing

Mobilize your Website

View Site in Mobile | Classic

Share by: